Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.
about
Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) testHPV-Testing in Follow-up of Patients Treated for CIN2+ LesionsE6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspectiveDeciphering the Multifactorial Susceptibility of Mucosal Junction Cells to HPV Infection and Related Carcinogenesis.Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya.High-risk human papillomavirus correlates with recurrence after laser ablation for treatment of patients with cervical intraepithelial neoplasia 3: a long-term follow-up retrospective study.Past and future of prophylactic ablation of the cervical squamocolumnar junctionPerformance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma.Long-Term Clinical Outcome after Treatment for High-Grade Cervical Lesions: A Retrospective Monoinstitutional Cohort StudyPosttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis.Positive Surgical Margin, HPV Persistence, and Expression of Both TPX2 and PD-L1 Are Associated with Persistence/Recurrence of Cervical Intraepithelial Neoplasia after Cervical Conization.The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women.Virological and cytological clearance in laser vaporization and conization for cervical intra-epithelial neoplasia grade 3.Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study.Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.The Clinical Role of HPV Testing in Primary and Secondary Cervical Cancer Screening.Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality.Understanding HPV tests and their appropriate applications.DNA methylation and detection of cervical cancer and precancerous lesions using molecular methods.An EM algorithm for nonparametric estimation of the cumulative incidence function from repeated imperfect test results.Follow up with HPV test and cytology as test of cure, 6 months after conization, is reliable.Treatment failure following excision therapy of CIN: the impact of direct colposcopic vision during procedure.Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.The negative conversion of high-risk human papillomavirus and its performance in surveillance of cervical cancer after treatment: a retrospective study.Multivariate analysis of risk factors for the persistence of high-grade squamous intraepithelial lesions following loop electrosurgical excision procedure.Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization.Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia.Risk factors for treatment failure following cold coagulation cervical treatment for CIN pathology: a cohort-based study.Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland.Cervical cancer: squamocolumnar junction ablation--tying up loose ends?The human papillomavirus Test of Cure: A lesson on compliance with the NHMRC guidelines on screening to prevent cervical cancer.Role of human papillomavirus testing and cytology in follow-up after conization.HPV and cervical cancer.Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction.Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H).Human papillomavirus type-specific persistence and recurrence after treatment for cervical dysplasia.Pregnancy outcomes after treatment for preinvasive cervical lesions.Markers of HPV infection and survival in patients with head and neck tumors.Long-term compliance with follow-up after treatment for cervical intra-epithelial neoplasia.
P2860
Q24186721-D42F0AF3-121E-41A8-B50F-04841B63A829Q26771420-528E8500-58C3-4C45-B2B5-29FA0890B346Q28087374-429778E8-3303-4170-A087-ABA500C305B3Q33613540-4382054E-79DA-45C9-A46E-455E9A6EE7FEQ34400805-98EA9A5A-78B1-48B4-8CD9-85D1353C6CE3Q35015627-025C6928-0ED1-4C00-9658-C78DDCC0B2CFQ35605616-AFD490C1-3A5A-481D-A27D-87A3AC3C53EDQ35605623-B5ADA3D0-EFB2-4396-B6A5-0D34FE700E6DQ35768850-956A4382-BDFA-45EB-BE31-DCB089F5D79BQ35805474-E469EFEC-F3EF-44DC-926C-96A2E0E41794Q35857079-CAE1D036-00BC-4CEA-A868-A0EC7585401AQ35984769-6DDD969B-EA37-4288-810D-454C99979312Q36015006-3A6A7C1A-044E-48A3-80F5-3F86E80B20BBQ36104392-28FE39C9-3A28-471B-BFE2-AC9FB0E28278Q36365581-D7887B0B-D853-43E2-8B2A-8DCF3E4CD8EEQ36739942-44B392E7-007E-44D8-BF23-841F6C014A29Q37018994-7B1024E2-EACE-47B1-B5EF-B56D05F83EC0Q37503431-C059F67E-D249-4392-84D3-7041527A050FQ38133612-9497CF26-3111-4F47-80D1-877E1ADFE7E1Q38605348-A2E787AA-A606-4240-9ECE-EBFE182EBD15Q38717960-CC0E7426-29A1-4B60-8BEB-B9858A2095B9Q40500436-2D3496A2-43A0-4E56-BC5F-244097B85CA2Q40504149-8ECF3A02-443C-4A34-A201-28ED7C7B70F6Q40525853-D532561D-CA33-40ED-8940-0B81452CDCF6Q40543250-B8942626-918D-49C4-BE79-9B2AF2634519Q40757847-CA2AF7DF-21DD-47D2-BAF9-CE214AAF1F8EQ40771931-ACC3D8E5-B6CC-4FB3-9B29-3285CB8DADDBQ40892020-D6D27F81-781D-4E3F-89B1-8C07947A747BQ40905270-181E9251-48C1-4C88-8F2B-5C4061CAC5B5Q40995859-453A01A9-8542-431E-A933-AEEB84D4DEF2Q41192227-72891636-C312-4395-9AAE-FE0317CC031BQ41336158-10905E39-2344-4CA7-9F54-5F2560A04DB2Q41489942-4F8A4B4A-32FF-4C90-BF2D-EA848EDCE15AQ42202437-99F61308-8445-4A85-A3E3-8B4FC6A7E243Q42217979-AE220326-02E5-4BA7-B1E1-B0381091F5F4Q42242703-79BD7C37-F08D-47B5-9BA0-866817ECF7A5Q42262648-A70F7224-B0CE-4BD1-A071-BC86FAB905FDQ42396590-E8A093AC-1C09-41C5-BD6A-970B134761EEQ46584014-D760F3C5-C9C8-4432-9A10-6FE78ED7BF4EQ47659950-1A17DF80-1958-40FB-A131-F4DB243B7C7B
P2860
Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Risk of recurrent high-grade c ...... long-term multi-cohort study.
@en
Risk of recurrent high-grade c ...... long-term multi-cohort study.
@nl
type
label
Risk of recurrent high-grade c ...... long-term multi-cohort study.
@en
Risk of recurrent high-grade c ...... long-term multi-cohort study.
@nl
prefLabel
Risk of recurrent high-grade c ...... long-term multi-cohort study.
@en
Risk of recurrent high-grade c ...... long-term multi-cohort study.
@nl
P2093
P1433
P1476
Risk of recurrent high-grade c ...... long-term multi-cohort study.
@en
P2093
Aagje G Bais
Chris J L M Meijer
Cornelis J A Hogewoning
Jacqueline A Louwers
Johannes Berkhof
Mariëlle A E Nobbenhuis
Mariëlle Kocken
Peter J F Snijders
René H M Verheijen
Theo J M Helmerhorst
P304
P356
10.1016/S1470-2045(11)70078-X
P50
P577
2011-05-01T00:00:00Z